Functional variants of IL4 and IL6 genes and risk of tobacco-related oral carcinoma in high-risk Asian Indians

Oral Diseases

Volumn 17, Issue 7, 2011, Pages 720-726

  Gaur, P ^a   Mittal, M ^a   Mohanti, B K ^a   Das, Satya N ^a  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

Author keywords

Asian Indians; Haplotype; IL4; IL6; Oral cancer; Single nucleotide polymorphisms

Indexed keywords

INTERLEUKIN 4; INTERLEUKIN 6;

ADULT; AGED; ALLELE; ARTICLE; ASIAN; CANCER RISK; CONTROLLED STUDY; FEMALE; GENE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HIGH RISK POPULATION; HUMAN; INDIAN; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; ORAL SQUAMOUS CELL CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL CARCINOMA; TOBACCO;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CYTOSINE; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; GUANINE; HAPLOTYPES; HUMANS; INDIA; INTERLEUKIN-4; INTERLEUKIN-6; MALE; MIDDLE AGED; MOUTH NEOPLASMS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RISK FACTORS; SMOKING; THYMINE; YOUNG ADULT;

EID: 80052559068     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2011.01831.x     Document Type: Article

References (40)

1. Agarwal A, Rani M, Saha GK et al (2003). Disregulated expression of the Th2 cytokine gene in patients with intraoral squamous cell carcinoma. Immunol Invest 32: 17-30.
2. Amirzargar AA, Movahedi M, Rezaei N et al (2009). Polymorphisms in IL4 and iIL ARA confer susceptibility to asthma. J Investig Allergol Clin Immunol 19: 433-438.
3. Asgeirsson KS, Olafsdottir K, Jonasson JG, Ogmundsdottir HM (1998). The effects of IL-6 on cell adhesion and e-cadherin expression in breast cancer. Cytokine 10: 720-728.
4. Badache A, Hynes NE (2001). Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells. Cancer Res 61: 383-391.
5. Baniasadi V, Narain N, Goswami R, Das SN (2006). Promoter region -318 C/T and -1661 A/G CTLA-4 single nucleotide polymorphisms and type 1diabetes in North Indians. Tissue Antigens 67: 383-389.
6. Boiardi L, Casali B, Farnetti E et al (2006). Relationship between interleukin 6 promoter polymorphism at position -174, IL6 serum levels, and the risk of relapse/recurrence in polymyalgia rheumatica. J Rheumatol 33: 703-708.
7. Cacev T, Jokic M, Loncar B, Krizanac S, Kapitanovic S (2010). Interleukin-6 -174 G/C polymorphism is not associated with IL-6 expression and susceptibility to sporadic colon cancer. DNA Cell Biol 29: 177-182.
8. Choi EH, Lee HJ, Yoo T, Chanock SJ (2002). A common haplotype of interleukin-4 gene IL4 is associated with severe respiratory syncytial virus disease in Korean children. J Infect Dis 186: 1207-1211.
9. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ (1996). Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 271: 736-741.
10. Coussens LM, Werb Z (2002). Inflammation and cancer. Nature 420: 860-867.
11. De Jong KP, Van Gameren MM, Bijzet J et al (2001). Recombinant human Interleukin-6 induces hepatocyte growth factor production in cancer patients. Scand J Gastroenterol 36: 636-640.
12. DeMichele A, Martin AM, Mick R et al (2003). Interleukin-6 -174G->C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res 63: 8051-8056.
13. Diehl S, Rincon M (2002). The two faces of IL-6 on Th1/Th2 differentiation. Mol Immunol 39: 531-536.
14. GLOBOCAN (2005) Cancer incidence, mortality and prevalence world-wide, version 1.0. IARC Press: Lyon, IARC Cancer Base No. 5.
15. Golumbek PT, Lazenby AJ, Levitsky HI et al (1991). Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254: 713-716.
16. Hefler LA, Grimm C, Ackermann S et al (2003). An Interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. Cancer Res 63: 3066-3068.
17. Hefler LA, Grimm C, Lantzsch T et al (2005). Interleukin-1 and Interleukin-6 gene polymorphisms and the risk of breast cancer in Caucasian women. Clin Cancer Res 11: 5718-5721.
18. Hegab AE, Sakamoto T, Saitoh W et al (2004). Polymorphisms of IL4, IL13 and ADRB2 genes in COPD. Chest 126: 1832-1839.
19. Hutchins D, Steel CM (1994). Regulation of ICAM-1 (CD54) expression in human breast cancer cell lines by Interleukin 6 and fibroblast-derived factors. Int J Cancer 58: 80-84.
20. Jin P, Panelli MC, Marincola FM, Wang E (2004). Cytokine polymorphism and its possible impact on cancer. Immunol Res 30: 181-190.
21. Kleinrath T, Gassner C, Lackner P, Thurnher M, Ramoner R (2007). Interleukin-4 promoter polymorphisms: a genetic prognostic factor for survival in metastatic renal cell carcinoma. J Clin Oncol 25: 845-851.
22. Landi S, Moreno V, Giola-Patricola L et al (2003). Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res 63: 3560-3566.
23. Landi S, Bottari F, Gemignani F et al (2007). Interleukin-4 and interleukin-4 receptor polymorphisms and colorectal cancer risk. Eur J Cancer 43: 762-768.
24. Manchanda P, Sharma SC, Das SN (2006). Differential regulation of IL-2 and IL-4 in patients with tobacco-related oral squamous cell carcinoma. Oral Dis 12: 455-462.
25. Nakashima H, Miyake K, Inoue Y et al (2002). Association between IL-4 genotype and IL-4 production in the Japanese population. Genes Immun 3: 107-109.
26. Ozgen AG, Karadeniz M, Erdogan M, Berdeli A, Saygili F, Yilmaz C (2009). The (-174) G/C polymorphism in the interleukin-6 gene is associated with risk of papillary thyroid carcinoma in Turkish patients. J Endocrinol Invest 32: 491-494.
27. Ries LAG, Eisner MP, Kosary CL et al (2005). SEER cancer statistics review, 1975-2002. National Cancer Institute: Bethesda, MD. Available at: [accessed on 18 April 2011].
28. Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y (2004). Cytokines in cancer immunity and immunotherapy. Immunol Rev 202: 275-293.
29. Spaner DE (2004). Amplifying cancer vaccine responses by modifying pathogenic gene programs in tumor cells. J Leukoc Biol 76: 338-351.
30. Terry CF, Loukaci V, Green FR (2000). Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 275: 18138-18144.
31. TNM classification of Oral Cancer - UICC (2002). In: Sobin LH, Wittekind Ch, eds. TNM classification of malignant tumors. 6th edn. Wiely-Liss: New York, NY, pp. 25-27.
32. Toi M, Bicknell R, Harris AL (1992). Inhibition of colon and breast carcinoma cell growth by Interleukin-4. Cancer Res 52: 275-279.
33. Tsezou A, Poultsides L, Kostopoulou F et al (2008). Influence of interleukin 1alpha (IL-1alpha), IL-4 and IL-6 polymorphisms on genetic susceptibility to chronic osteomyelitis. Clin Vaccine Immunol 15: 1888-1890.
34. Uchiyama A, Essner R, Doi F et al (1996). Interleukin 4 inhibits hepatocyte growth factor-induced invasion and migration of colon carcinomas. J Cell Biochem 62: 443-453.
35. Watson JM, Sensintaffar JL, Berek JS, Martinez-Maza O (1990). Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res 50: 6959-6965.
36. Wilkening S, Tavelin B, Canzian F et al (2008). Interleukin promoter polymorphisms and prognosis in colorectal cancer. Carcinogenesis 29: 1202-1206.
37. Wu J, Lu Y, Ding YB et al (2009). Promoter polymorphisms of IL2, IL4 and risk of gastric cancer risk in a high-risk Chinese population. Mol Carcinog 48: 626-632.
38. Yu SJ, Kim HS, Cho SW, Sohn J (2004). IL-4 inhibits proliferation of renal carcinoma cells by increasing the expression of p21WAF1 and IRF-1. Exp Mol Med 36: 372-379.
39. Yu KD, Di GH, Fan L, Chen AX, Yang C, Shao ZM (2010). Lack of association between a functional polymorphism in the Interleukin-6 gene promoter and breast cancer risk: a meta-analysis involving 25, 703 subjects. Breast Cancer Res Treat 122: 483-488.
40. Zhu J, Ju X, Yan F et al (2010). Association of IL4 -590 T>C polymorphism and risk of renal cell carcinoma in Chinese population. Int J Immunogenet 37: 459-465.